ArticleJCEM case reports2026
Ethiodized oil interference of planned radioiodine therapy post thoracic duct embolization: report of 2 cases.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioiodine (RAI) therapy is considered in differentiated thyroid cancers (DTC) following surgery. While rare, a severe chyle leak (CL) resulting from surgery may require treatment with thoracic duct embolization (TDE) following lymphangiography. These procedures involve the administration of ethiodized oil into the central lymphatics. Herein, we present 2 cases-a 67-year-old man and a 21-year-old woman-diagnosed with papillary thyroid cancer who, following total thyroidectomy and neck dissection, developed a postoperative CL that was treated with TDE. Despite 12 weeks between TDE and evaluation for RAI therapy in both cases, nonradioactive iodine from ethiodized oil resulted in an excess urinary iodine concentration, potentially significant interference of RAI uptake, decreased diagnostic sensitivity, and reduced therapeutic efficacy. The 67-year-old man was evaluated for RAI therapy twice but did not receive treatment, whereas the 21-year-old woman received RAI therapy at initial evaluation despite excess iodine present. Potential interference of ethiodized oil on RAI imaging and therapy should be considered when selecting treatment for a severe CL and when evaluating the utility of RAI therapy after lymphatic interventions involving ethiodized oil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.